Pablo Umana

This inventor holds 88 USPTO granted patents and 143 published patent applications, plus 28 CIPO patents and 71 EPO patents, primarily in Bispecific Antibodies (CPC class C07K2317-92). Top assignees: Hoffmann-La Roche Inc., Roche Glycart Ag, Engmab Sarl. Active years: 2011-2026.

USPTO Granted Patents = 88 (Patent Applications = 143)

% Patents Active = 85.2

CIPO Patents = 28 (Patent Applications = 54)

EPO Patents = 71 (Patent Applications = 85)

Average Co-Inventor Count = 7.0

ph-index = 17

Forward Citations = 908(Granted Patents)

Forward Citations (Not Self Cited) = 582(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Zurich, CH (2011 - 2018)
Waedenswil, CH (2018 - 2022)
Wollerau, CH (2014 - 2024)
Schlieren, CH (2019 - 2024)

Company Filing History:

40 out of 5,016

Hoffmann-La Roche Inc.

Bristol-Myers Squibb Compnay

Glycart Biotechnology Ag

8. 1 out of 834,350

Other

patents

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Cancer Treatment

TNF Family Ligand

T Cell Activation

Immunoconjugates

4-1BB Agonists

Anti-FAP

PD-1 Targeting

Interleukin-2

HER2-targeting

NKG2D

CD3EPSILON

88 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735485 - BISPECIFIC ANTIGEN BINDING MOLECULES TARGETING OX40 AND FAP (2026-09-15),

2. 12723084 - 4-1BBL TRIMER-CONTAINING ANTIGEN BINDING MOLECULES (2026-09-01),

3. 12637522 - MONOCLONAL ANTIBODIES AGAINST BCMA (2026-05-26),

4. 12441812 - Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules (2025-10-14),

5. 12286486 - Anti-FAP antibodies and methods of use (2025-04-29),

6. 12281153 - Combination therapy with targeted 4-1BB (CD137) agonists (2025-04-21),

7. 12275794 - Bispecific antigen binding molecules comprising anti-FAP clone 212 (2025-04-14),

8. 12258371 - Stabilized immunoglobulin domains (2025-03-25),

9. 12240911 - Bispecific antibodies specific for OX40 (2025-03-04),

10. 12202870 - Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof (2025-01-21),

11. 12139553 - T cell activating bispecific antigen binding molecules (2024-11-12),

12. 12103982 - T cell activating bispecific antigen binding molecules (2024-10-01),

13. 12065478 - HER2-targeting antigen binding molecules comprising 4-1BBL (2024-08-20),

14. 12023368 - Immunoconjugates (2024-07-02),

15. 11952421 - Bispecific antibodies against CD3EPSILON and ROR1 (2024-04-09),

Title: Inventor Pablo Umana - Revolutionizing Technology in Wollerau

Introduction: Pablo Umana is a visionary inventor based in Wollerau, Switzerland, known for his groundbreaking contributions to the field of technology.

Latest Patents: Pablo Umana holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and innovation.

Career Highlights: With a career spanning over two decades, Pablo Umana has worked with leading tech companies to develop cutting-edge solutions that have had a significant impact on various industries.

Collaborations: Throughout his career, Pablo Umana has collaborated with top researchers, engineers, and scientists from around the world, fostering a culture of innovation and excellence in all his projects.

Conclusion: Pablo Umana's relentless pursuit of innovation and his passion for pushing the boundaries of technology make him a true pioneer in the field of inventions, with a lasting legacy that continues to inspire future generations.